# Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients

> **NCT00622089** · PHASE2,PHASE3 · TERMINATED · sponsor: **DiObex** · enrollment: 150 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** DIO-902
- **DRUG:** DIO-902
- **DRUG:** DIO-902

## Key facts

- **NCT ID:** NCT00622089
- **Lead sponsor:** DiObex
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 150 (ESTIMATED)
- **Why stopped:** Program terminated
- **Last updated:** 2008-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00622089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00622089, "Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00622089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*